ACS Publications. Most Trusted. Most Cited. Most Read
My Activity
CONTENT TYPES

Investigating the Domain Specificity of Phosphinic Inhibitors RXPA380 and RXP407 in Angiotensin-Converting Enzyme

View Author Information
Division of Medical Biochemistry, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town 7935, South Africa
§ Department of Biochemistry, North-West University, Potchefstroom 2531, South Africa
CEA, iBiTecS, Service d'Ingénierie Moléculaire des Protéines (SIMOPRO), Gif sur Yvette F-91191, France
*Address correspondence to this author. Telephone: +27 21 406 6312. Fax: +27 21 406 6470. E-mail: [email protected]
Cite this: Biochemistry 2009, 48, 35, 8405–8412
Publication Date (Web):August 6, 2009
https://doi.org/10.1021/bi9011226
Copyright © 2009 American Chemical Society

    Article Views

    653

    Altmetric

    -

    Citations

    LEARN ABOUT THESE METRICS
    Other access options

    Abstract

    Abstract Image

    Human somatic angiotensin-converting enzyme (ACE) is a membrane-bound dipeptidyl carboxypeptidase that contains two extracellular domains (N and C). Although highly homologous, they exhibit different substrate and inhibition profiles. The phosphinic inhibitors RXPA380 and RXP407 are highly selective for the C- and N-domains, respectively. A number of residues, implicated by structural data, are likely to contribute to this selectivity. However, the extent to which these different interactions are responsible for domain selectivity is unclear. In this study, a series of C- and N-domain mutants containing conversions to corresponding domain residues were used to scrutinize the contribution of these residues to selective inhibitor binding. Enzyme kinetic analyses of the purified mutants indicated that the RXPA380 C-selectivity is particularly reliant on the interaction between the P2 substituent and Phe 391 (testis ACE numbering). Moreover, a C-domain mutant in which Phe 391 has been changed to a Tyr residue, in addition to containing an N-domain S2′ pocket (S2′F/Y), displayed the greatest shift toward a more N-domain-like Ki. None of the single mutations within the N-domain caused a large shift in RXP407’s affinity for these enzymes. However, the double mutant containing the Tyr 369 to Phe change as well as Arg 381 to Glu displayed a 100-fold decrease in binding affinity, confirming that the S2 pocket plays a major role in RXP407 selectivity. Taken together, these data advance our understanding regarding the molecular basis for the remarkable ACE domain selectivity exhibited by these inhibitors.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.

    Recommended

    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

    Cited By

    This article is cited by 37 publications.

    1. Dimitris Georgiadis, Nikolaos Skoulikas, Athanasios Papakyriakou, Efstratios Stratikos. Phosphinic Peptides as Tool Compounds for the Study of Pharmacologically Relevant Zn-Metalloproteases. ACS Pharmacology & Translational Science 2022, 5 (12) , 1228-1253. https://doi.org/10.1021/acsptsci.2c00183
    2. Lauren B. Arendse, Gyles E. Cozier, Charles J. Eyermann, Gregory S. Basarab, Sylva L. Schwager, Kelly Chibale, K. Ravi Acharya, Edward D. Sturrock. Probing the Requirements for Dual Angiotensin-Converting Enzyme C-Domain Selective/Neprilysin Inhibition. Journal of Medicinal Chemistry 2022, 65 (4) , 3371-3387. https://doi.org/10.1021/acs.jmedchem.1c01924
    3. Chang Liu, Jingbo Liu, Manqiu Wang, Biying Zhang, Erlei Wang, Boqun Liu, Ting Zhang. Construction and Application of Membrane-Bound Angiotensin-I Converting Enzyme System: A New Approach for the Evaluation of Angiotensin-I Converting Enzyme Inhibitory Peptides. Journal of Agricultural and Food Chemistry 2020, 68 (20) , 5723-5731. https://doi.org/10.1021/acs.jafc.9b08082
    4. Gyles E. Cozier, Lauren B. Arendse, Sylva L. Schwager, Edward D. Sturrock, K. Ravi Acharya. Molecular Basis for Multiple Omapatrilat Binding Sites within the ACE C-Domain: Implications for Drug Design. Journal of Medicinal Chemistry 2018, 61 (22) , 10141-10154. https://doi.org/10.1021/acs.jmedchem.8b01309
    5. Stephen Fienberg, Gyles E. Cozier, K. Ravi Acharya, Kelly Chibale, and Edward D. Sturrock . The Design and Development of a Potent and Selective Novel Diprolyl Derivative That Binds to the N-Domain of Angiotensin-I Converting Enzyme. Journal of Medicinal Chemistry 2018, 61 (1) , 344-359. https://doi.org/10.1021/acs.jmedchem.7b01478
    6. Rajni K. Sharma, Marlene Espinoza-Moraga, Horacio Poblete, Ross G. Douglas, Edward D. Sturrock, Julio Caballero, and Kelly Chibale . The Dynamic Nonprime Binding of Sampatrilat to the C-Domain of Angiotensin-Converting Enzyme. Journal of Chemical Information and Modeling 2016, 56 (12) , 2486-2494. https://doi.org/10.1021/acs.jcim.6b00524
    7. Faïza Zidane, Gabrielle Zeder-Lutz, Danièle Altschuh, Jean-Michel Girardet, Laurent Miclo, Catherine Corbier, and Céline Cakir-Kiefer . Surface Plasmon Resonance Analysis of the Binding Mechanism of Pharmacological and Peptidic Inhibitors to Human Somatic Angiotensin I-Converting Enzyme. Biochemistry 2013, 52 (48) , 8722-8731. https://doi.org/10.1021/bi4006144
    8. Artur Mucha, Paweł Kafarski, and Łukasz Berlicki . Remarkable Potential of the α-Aminophosphonate/Phosphinate Structural Motif in Medicinal Chemistry. Journal of Medicinal Chemistry 2011, 54 (17) , 5955-5980. https://doi.org/10.1021/jm200587f
    9. Nicolas Jullien, Anastasios Makritis, Dimitris Georgiadis, Fabrice Beau, Athanasios Yiotakis and Vincent Dive . Phosphinic Tripeptides as Dual Angiotensin-Converting Enzyme C-Domain and Endothelin-Converting Enzyme-1 Inhibitors. Journal of Medicinal Chemistry 2010, 53 (1) , 208-220. https://doi.org/10.1021/jm9010803
    10. Moaz M. Abdou, Dewen Dong, Paul M. O'Neill, Eric Amigues, Magdalini Matziari. Diastereoselective synthesis of a novel phosphinic peptide as ACE inhibitor: Fragment-based design approach. Arabian Journal of Chemistry 2023, 16 (2) , 104499. https://doi.org/10.1016/j.arabjc.2022.104499
    11. Wenyue Zheng, Erkang Tian, Zhen Liu, Changhan Zhou, Pei Yang, Keyue Tian, Wen Liao, Juan Li, Changyu Ren. Small molecule angiotensin converting enzyme inhibitors: A medicinal chemistry perspective. Frontiers in Pharmacology 2022, 13 https://doi.org/10.3389/fphar.2022.968104
    12. Lizelle Lubbe, Bryan Trevor Sewell, Jeremy D Woodward, Edward D Sturrock. Cryo‐EM reveals mechanisms of angiotensin I‐converting enzyme allostery and dimerization. The EMBO Journal 2022, 41 (16) https://doi.org/10.15252/embj.2021110550
    13. Neng-Yao Goh, Muhammad Fazril Mohamad Razif, Yeannie Hui-Yeng Yap, Chyan Leong Ng, Shin-Yee Fung. In silico analysis and characterization of medicinal mushroom cystathionine beta-synthase as an angiotensin converting enzyme (ACE) inhibitory protein. Computational Biology and Chemistry 2022, 96 , 107620. https://doi.org/10.1016/j.compbiolchem.2021.107620
    14. Cheng‐Cheng Song, Bian‐Wen Qiao, Qin Zhang, Chen‐Xin Wang, Ying‐Huan Fu, Bei‐Wei Zhu. Study on the domain selective inhibition of angiotensin‐converting enzyme (ACE) by food‐derived tyrosine‐containing dipeptides. Journal of Food Biochemistry 2021, 45 (7) https://doi.org/10.1111/jfbc.13779
    15. Edward D. Sturrock, K. Ravi Acharya. ACE Inhibitors. 2021, 8-17. https://doi.org/10.1007/978-3-030-57401-7_1
    16. Moaz M. Abdou. Synopsis of recent synthetic methods and biological applications of phosphinic acid derivatives. Tetrahedron 2020, 76 (25) , 131251. https://doi.org/10.1016/j.tet.2020.131251
    17. Gyles E. Cozier, Lizelle Lubbe, Edward D. Sturrock, K. Ravi Acharya. ACE-domain selectivity extends beyond direct interacting residues at the active site. Biochemical Journal 2020, 477 (7) , 1241-1259. https://doi.org/10.1042/BCJ20200060
    18. Edward D. Sturrock, K. Ravi Acharya. ACE Inhibitors. 2020, 1-11. https://doi.org/10.1007/978-3-030-21573-6_1-1
    19. Lauren B. Arendse, A. H. Jan Danser, Marko Poglitsch, Rhian M. Touyz, John C. Burnett, Catherine Llorens-Cortes, Mario R. Ehlers, Edward D. Sturrock, . Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure. Pharmacological Reviews 2019, 71 (4) , 539-570. https://doi.org/10.1124/pr.118.017129
    20. Mája Polakovičová, Josef Jampílek. Advances in Structural Biology of ACE and Development of Domain Selective ACE-inhibitors. Medicinal Chemistry 2019, 15 (6) , 574-587. https://doi.org/10.2174/1573406415666190514081132
    21. Edward D. Sturrock, Lizelle Lubbe, Gyles E. Cozier, Sylva L.U. Schwager, Afolake T. Arowolo, Lauren B. Arendse, Emma Belcher, K. Ravi Acharya. Structural basis for the C-domain-selective angiotensin-converting enzyme inhibition by bradykinin-potentiating peptide b (BPPb). Biochemical Journal 2019, 476 (10) , 1553-1570. https://doi.org/10.1042/BCJ20190290
    22. Melanie Martin, Andreas Deussen. Effects of natural peptides from food proteins on angiotensin converting enzyme activity and hypertension. Critical Reviews in Food Science and Nutrition 2019, 59 (8) , 1264-1283. https://doi.org/10.1080/10408398.2017.1402750
    23. Vladimir R. Vukic, Dajana V. Vukic, Spasenija D. Milanovic, Mirela D. Ilicic, Katarina G. Kanuric, Mark S. Johnson. In silico identification of milk antihypertensive di- and tripeptides involved in angiotensin I–converting enzyme inhibitory activity. Nutrition Research 2017, 46 , 22-30. https://doi.org/10.1016/j.nutres.2017.07.009
    24. Lizelle Lubbe, Brian T. Sewell, Edward D. Sturrock. The influence of angiotensin converting enzyme mutations on the kinetics and dynamics of N‐domain selective inhibition. The FEBS Journal 2016, 283 (21) , 3941-3961. https://doi.org/10.1111/febs.13900
    25. Geoffrey Masuyer, Ross G. Douglas, Edward D. Sturrock, K. Ravi Acharya. Structural basis of Ac-SDKP hydrolysis by Angiotensin-I converting enzyme. Scientific Reports 2015, 5 (1) https://doi.org/10.1038/srep13742
    26. Diana Lunow, Susanne Kaiser, Jana Rückriemen, Christoph Pohl, Thomas Henle. Tryptophan-containing dipeptides are C-domain selective inhibitors of angiotensin converting enzyme. Food Chemistry 2015, 166 , 596-602. https://doi.org/10.1016/j.foodchem.2014.06.059
    27. Charlotte Harrison, K. Ravi Acharya. ACE for all – a molecular perspective. Journal of Cell Communication and Signaling 2014, 8 (3) , 195-210. https://doi.org/10.1007/s12079-014-0236-8
    28. Keizo Kanasaki, Takako Nagai, Kyoko Nitta, Munehiro Kitada, Daisuke Koya. N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes. Frontiers in Pharmacology 2014, 5 https://doi.org/10.3389/fphar.2014.00070
    29. Ross G. Douglas, Rajni K. Sharma, Geoffrey Masuyer, Lizelle Lubbe, Ismael Zamora, K. Ravi Acharya, Kelly Chibale, Edward D. Sturrock. Fragment-based design for the development of N-domain-selective angiotensin-1-converting enzyme inhibitors. Clinical Science 2014, 126 (4) , 305-313. https://doi.org/10.1042/CS20130403
    30. Takako Nagai, Megumi Kanasaki, Swayam Prakash Srivastava, Yuka Nakamura, Yasuhito Ishigaki, Munehiro Kitada, Sen Shi, Keizo Kanasaki, Daisuke Koya. N-acetyl-seryl-aspartyl-lysyl-proline Inhibits Diabetes-Associated Kidney Fibrosis and Endothelial-Mesenchymal Transition. BioMed Research International 2014, 2014 , 1-12. https://doi.org/10.1155/2014/696475
    31. Kenneth E. Bernstein, Frank S. Ong, Wendell-Lamar B. Blackwell, Kandarp H. Shah, Jorge F. Giani, Romer A. Gonzalez-Villalobos, Xiao Z. Shen, Sebastien Fuchs, . A Modern Understanding of the Traditional and Nontraditional Biological Functions of Angiotensin-Converting Enzyme. Pharmacological Reviews 2013, 65 (1) , 1-46. https://doi.org/10.1124/pr.112.006809
    32. Geoffrey Masuyer, Sylva L. U. Schwager, Edward D. Sturrock, R. Elwyn Isaac, K. Ravi Acharya. Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides. Scientific Reports 2012, 2 (1) https://doi.org/10.1038/srep00717
    33. Ross G. Douglas, Edward D. Sturrock. Structure-Based Design of Domain-Selective Angiotensin-Converting Enzyme Inhibitors. 2012, 355-377. https://doi.org/10.1007/978-3-642-28175-4_15
    34. Megumi Kanasaki, Takako Nagai, Munehiro Kitada, Daisuke Koya, Keizo Kanasaki. Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors. Fibrogenesis & Tissue Repair 2011, 4 (1) https://doi.org/10.1186/1755-1536-4-25
    35. Colin S. Anthony, Hazel R. Corradi, Sylva L.U. Schwager, Pierre Redelinghuys, Dimitris Georgiadis, Vincent Dive, K. Ravi Acharya, Edward D. Sturrock. The N Domain of Human Angiotensin-I-converting Enzyme. Journal of Biological Chemistry 2010, 285 (46) , 35685-35693. https://doi.org/10.1074/jbc.M110.167866
    36. Mohd Akif, Dimitris Georgiadis, Aman Mahajan, Vincent Dive, Edward D. Sturrock, R. Elwyn Isaac, K. Ravi Acharya. High-Resolution Crystal Structures of Drosophila melanogaster Angiotensin-Converting Enzyme in Complex with Novel Inhibitors and Antihypertensive Drugs. Journal of Molecular Biology 2010, 400 (3) , 502-517. https://doi.org/10.1016/j.jmb.2010.05.024
    37. Jean M. Watermeyer, Wendy L. Kröger, Hester G. O'Neill, B. Trevor Sewell, Edward D. Sturrock. Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril. Biochemical Journal 2010, 428 (1) , 67-74. https://doi.org/10.1042/BJ20100056

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    You’ve supercharged your research process with ACS and Mendeley!

    STEP 1:
    Click to create an ACS ID

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    MENDELEY PAIRING EXPIRED
    Your Mendeley pairing has expired. Please reconnect